Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

12.59USD
26 May 2017
Change (% chg)

$-0.16 (-1.25%)
Prev Close
$12.75
Open
$12.69
Day's High
$12.78
Day's Low
$12.44
Volume
142,844
Avg. Vol
328,735
52-wk High
$16.50
52-wk Low
$4.03

Latest Key Developments (Source: Significant Developments)

PTC enters into credit and security agreement for senior secured term loan facility
Monday, 8 May 2017 07:44am EDT 

May 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics inc- on may 5, entered into a credit and security agreement for a senior secured term loan facility of $60.0 million - sec filing.Ptc therapeutics inc- final maturity date under credit agreement is may 1, 2021.Ptc therapeutics inc - on loan facility of $60.0 million, $40.0 million was drawn by company on may 5, 2017.Ptc therapeutics-$20.0 million under facility available upon co's demonstration, on/prior to dec 31, 2018, of net product revenue equaling/exceeding $120 million.  Full Article

PTC Therapeutics qtrly loss per share $0.85
Monday, 8 May 2017 07:30am EDT 

May 8 (Reuters) - PTC Therapeutics Inc : :Qtrly loss per share $0.85.Qtrly total revenues $26,5 million versus $18.9 million.PTC Therapeutics Inc - translarna net sales for 2017 are now anticipated to be between $115 and $130 million.PTC Therapeutics Inc -GAAP operating expenses for full year 2017 are anticipated to be between $250 to $260 million.  Full Article

Complete Pharma reports 16.2 pct passive stake in PTC Therapeutics
Thursday, 27 Apr 2017 06:08pm EDT 

April 27 (Reuters) - Ptc Therapeutics Inc :Complete Pharma Holdings II LLC reports 16.2 percent passive stake in PTC Therapeutics Inc as on April 20, 2017 - SEC filing.  Full Article

PTC Therapeutics reports departure of CFO
Monday, 10 Apr 2017 04:01pm EDT 

PTC Therapeutics Inc : PTC Therapeutics announces departure of chief financial officer, Shane Kovacs . PTC Therapeutics Inc says PTC has initiated a search process to appoint a new CFO .PTC Therapeutics - Shane is expected to remain with PTC through closing of PTC's pending acquisition of all rights to emflaza from Marathon Pharma.  Full Article

PTC says they "plan to re-examine the price of Emflaza": Conf Call
Thursday, 16 Mar 2017 08:00am EDT 

PTC Therapeutics Inc : PTC says prior to FDA approval, access to Emflaza has been limited to small number of patients, "We aim to close this gap with the launch": Conf Call . PTC says deal will diversify its business, enabling revenue generation through 2 products, & expanding commercial geographic footprint to include us: Conf Call . PTC says they "plan to re-examine the price of Emflaza": Conf Call . PTC says Emflaza launch would enable it to establish a complete U.S medical sales and marketing footprint ahead of a potential Translarna launch : Conf Call . PTC says anticipate an increase in operating expenses in 2017 : Conf Call . PTC says Emflaza sales are expected to begin later this year : Conf Call . PTC says "we appreciate that pricing is receiving a lot of attention and we believe that a change needs to be made": Conf Call . PTC says "ensuring access to the drug (Emflaza) is a priority and until recently only a small fraction of patients had access": Conf Call . PTC says it's "premature" to comment on exactly what that price level (for Emflaza) is going to be at this time: Conf Call . PTC "we'll think about updating our guidance in terms of operating expenses probably on our Q1 call as we close the (Emflaza) launch & finalize plan: Conf Call . PTC says "really prior to this approval there is really less than 10 percent of patients that were able to get Emflaza": Conf Call.  Full Article

PTC Therapeutics reports Q4 loss per share of $0.78
Thursday, 16 Mar 2017 07:30am EDT 

Ptc Therapeutics Inc : Total revenues for Q4 of 2016 were $25.2 million versus $12.7 million in same period of 2015 . For 2017, ptc expects to achieve ex-U.S. Translarna net sales between $105 and $125 million . Net loss for Q4 of 2016 was $26.8 million compared to a net loss of $50.9 million for same period in 2015 . PTC is reviewing its guidance for 2017 operating expenses and ending cash in light of PTC's planned acquisition of Emflaza . Translarna net product sales were $25.1 million for Q4 of 2016, representing 98 pct growth versus $12.7 million in Q4 of 2015 . Two SMA clinical trials on track to advance into pivotal studies in 2017 . Qtrly loss per share $0.78 .Q4 earnings per share view $-1.07, revenue view $24.0 million -- Thomson Reuters I/B/E/S.  Full Article

PTC Therapeutics to buy Emflaza
Thursday, 16 Mar 2017 07:15am EDT 

PTC Therapeutics Inc : PTC Therapeutics announces agreement to acquire Emflaza™ for the treatment of duchenne muscular dystrophy in U.S. . PTC Therapeutics Inc- transaction is expected to be accretive to both earnings and cash flow beginning in 2018 . PTC Therapeutics Inc - deal comprised of approximately $75 million in cash and approximately $65 million in PTC common stock . PTC Therapeutics Inc- in addition, marathon has opportunity to receive a single $50 million sales-based milestone . PTC Therapeutics Inc - deal for $140 million upfront consideration . PTC Therapeutics Inc - Marathon is also entitled to receive payments from ptc based on annual net sales of emflaza beginning in 2018 .PTC Therapeutics Inc- has entered into an asset purchase agreement with Marathon Pharmaceuticals, Llc to acquire all rights to emflaza.  Full Article

PTC Therapeutics announces FDA acknowledgment of NDA filing for translarna
Monday, 6 Mar 2017 08:00am EST 

PTC Therapeutics Inc : PTC Therapeutics announces FDA acknowledgment of new drug application filing for translarna for the treatment of nonsense mutation duchenne muscular dystrophy .Fda has assigned a PDUFA date of October 24, 2017.  Full Article

PTC Therapeutics says EU ratifies positive CHMP opinion for renewal of Translarna
Monday, 9 Jan 2017 05:48pm EST 

Ptc Therapeutics Inc - :PTC therapeutics - European Commission adopted positive decision granting annual renewal of conditional marketing authorization for translarna.  Full Article

PTC Therapeutics provides corporate update
Monday, 9 Jan 2017 08:00am EST 

PTC Therapeutics Inc : Preliminary 2016 translarna unaudited net sales of approximately $81 million . Translarna 2017 net sales guidance of $105 to $125 million . Topline act cf data anticipated late Q1 2017 . Non-GAAP operating expenses for 2017 are expected to be between $190 and $200 million .PTC expects to finish 2017 with approximately $160 million of cash and cash equivalents.  Full Article

More From Around the Web

BRIEF-PTC enters into credit and security agreement for senior secured term loan facility

* Ptc therapeutics inc- on may 5, entered into a credit and security agreement for a senior secured term loan facility of $60.0 million - sec filing